Anterogen.Co.,Ltd. (KOSDAQ:065660)
South Korea · Delayed Price · Currency is KRW 38,300
+400 (1.06%)
Apr 10, 2026, 3:30 PM KST
Anterogen.Co.,Ltd. Revenue
In the year 2025, Anterogen.Co.,Ltd. had annual revenue of 7.54B KRW with 8.71% growth. Anterogen.Co.,Ltd. had revenue of 2.00B in the quarter ending December 31, 2025, with 12.04% growth.
Revenue
7.54B
Revenue Growth
+8.71%
P/S Ratio
50.32
Revenue / Employee
n/a
Employees
n/a
Market Cap
379.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.54B | 603.60M | 8.71% |
| Dec 31, 2024 | 6.93B | 432.62M | 6.66% |
| Dec 31, 2023 | 6.50B | -90.76M | -1.38% |
| Dec 31, 2022 | 6.59B | -1.53B | -18.85% |
| Dec 31, 2021 | 8.12B | 3.97B | 95.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Holdings | 2.45T |
| EASY BIO,Inc. | 476.94B |
| Bioneer | 330.11B |
| Medy-Tox | 247.29B |
| BINEX | 168.47B |
| GC Cell | 165.52B |
| JETEMA, | 76.90B |
| HLB Therapeutics | 69.56B |